Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Gene Therapy

• Publication date

  2001-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.cgt.7700351PMID 11593334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue

  2000cited by this paper
• Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses.

  2000cited by this paper
• Therapeutic vaccination for cancer.

  2000cited by this paper
• Design and evaluation of antigen-specific vaccination strategies against cancer.

  2000cited by this paper
• Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.

  2000cited by this paper
• Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A31

  2000cited by this paper
• Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant

  2000cited by this paper
• Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

  1999cited by this paper
• Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.

  1999cited by this paper
• Generating MHC class I ligands from viral gene products

  1999cited by this paper
• Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

  1999cited by this paper
• The efficiency of antigen recognition by CD8+ CTL clones is determined by the frequency of serial TCR engagement.

  1998cited by this paper
• HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.

  1998cited by this paper
• MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL.

  1997cited by this paper
• Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

  1997cited by this paper
• MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies.

  1997cited by this paper
• Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.

  1997cited by this paper
• Heterogeneity of biologic responses of melanoma-specific CTL.

  1997cited by this paper
• Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication‐incompetent vaccinia virus encoding MART‐1/Melan‐A 27‐35 epitope

  1997influential reference
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996cited by this paper
• Processing and delivery of peptides presented by MHC class I molecules.

  1996cited by this paper
• Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

  1996cited by this paper
• Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light

  1996cited by this paper
• Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy

  1996cited by this paper
• High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12.

  1995cited by this paper
• Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patients

  1995cited by this paper
• TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide.

  1994cited by this paper

• The Role Microbiome and Oncolytic Viruses Play in Controlling Cancer

  2022cites this paper
• Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy

  2020cites this paper
• Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells

  2019cites this paper
• A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effects in vitro and in vivo

  2019cites this paper
• Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and "uncommon" strains.

  2014cites this paper
• Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials.

  2013cites this paper
• The Immune Response to a Vesicular Stomatitis Virus Vaccine Vector Is Independent of Particulate Antigen Secretion and Protein Turnover Rate

  2012cites this paper
• Selective Replicating Viral Vectors

  2012cites this paper
• Preventing vaccinia virus class‐I epitopes presentation by HSV‐ICP47 enhances the immunogenicity of a TAP‐independent cancer vaccine epitope

  2012cites this paper
• Clinical development directions in oncolytic viral therapy

  2011cites this paper
• Vaccinia virus expressing ICP47 : a novel platform for cancer vaccines highlighting tumor epitopes and hiding viral antigens

  2010influential citation
• Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.

  2008cites this paper
• Effective gene transfer to melanoma cells using bacterial ghosts.

  2008cites this paper
• Fighting cancer with vaccinia virus: teaching new tricks to an old dog.

  2005cites this paper
• Clinical applications of recombinant virus-based cancer immunotherapy

  2005cites this paper
• Poxvirus vaccines for cancer and HIV therapy

  2004cites this paper
• Oncolytic viral therapies

  2004cites this paper
• Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor-Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients

  2003cites this paper
• Gene therapy for cancer and metastatic disease

  2003cites this paper
• Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells

  2003cites this paper
• Rational approaches to human cancer immunotherapy

  2003cites this paper
• Poxviruses as vectors for cancer immunotherapy.

  2003cites this paper
• Antigen‐specific immunotherapy and cancer vaccines

  2003cites this paper
• Selectively replicating viral vectors

  2002cites this paper
• Clinical cancer vaccine trials.

  2002cites this paper